Companies · Biotech

Zivo Bioscience, Inc.

Bloomfield Hills · Biotech · refined from filed group “Other Health Care

Diligence memoA one-page analyst read on Zivo Bioscience, Inc. — recommendation, valuation, rhythm, risks.
$14.6M
Total raised · real
16
Rounds
0.8×
Latest step-up
Top 13%
Sector rank · raised
Recurring offerings
Latest stage · inferred · Fri Jun 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Zivo Bioscience, Inc. has raised $15M over 16 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

At-risk
  • Last raise 3.0 yr ago; this sector typically re-raises about every 11 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Recurring offering issuermedium confidence

Zivo Bioscience, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Program-like
Frequent filings and follow-ons read more like a securities offering program than discrete startup rounds.
Lifecycle
16.8 yr record
Peak capital year was 2009 with $22.3M across 20 filings.
Market position
ahead of 88% of Biotech peers
Capital scale is ahead of 88% of Biotech peers; modeled value is above 79% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Lower applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • 47 dated financing filings, averaging about 4 months apart.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2009: $22.3M across 20 filings.
  • Largest single filing was $5.0M on 2018-07-01.
  • Filing rows sum to $40.6M, while canonical raised total is $14.6M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech

Zivo Bioscience, Inc. is one of 233 Biotech companies tracked from Bloomfield Hills. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

biotech

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2023
Year incorporated
2023-06-30
First sale
Amount raised vs valuation, by year

This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Annual capital raised · realLatest value in year · estCumulative funded · real

Dense history compressed: 47 filings shown as 9 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.

$0$50M$100M$150M$200M2009: 20 filings Raised $22M total (real) Latest modeled valuation $31M (est)200920 filings2010: 1 filing Raised $675K total (real) Latest modeled valuation $37M (est)20101 filings2011: 13 filings Raised $4.7M total (real) Latest modeled valuation $43M (est)201113 filings2012: 5 filings Raised $1.5M total (real) Latest modeled valuation $6.2M (est)20125 filings2013: 4 filings Raised $1.1M total (real) Latest modeled valuation $11M (est)20134 filings2014: 1 filing Raised $100K total (real) Latest modeled valuation $4.4M (est)20141 filings2016: 1 filing Raised $1.3M total (real) Latest modeled valuation $56M (est)20161 filings2018: 1 filing Raised $5.0M total (real) Latest modeled valuation $181M (est)20181 filings2023: 1 filing Raised $4.0M total (real) Latest modeled valuation $34M (est)20231 filings+$675K+$4.7M+$1.5M+$1.1M+$100K+$1.3M+$5.0M+$4.0MCumulative $41M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps

This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.

Initial offering$500K · 2009
Follow-on offering$1.2M · 2009
Follow-on offering$1.7M · 2009
Follow-on offering$1.6M · 2009
Follow-on offering$1.4M · 2009
Follow-on offering$1.3M · 2009
Follow-on offering$524K · 2009
Follow-on offering$335K · 2009
Follow-on offering$1.6M · 2009
Follow-on offering$1.7M · 2009
Follow-on offering$1.5M · 2009
Follow-on offering$1.5M · 2009
Follow-on offering$1.4M · 2009
Follow-on offering$606K · 2009
Follow-on offering$983K · 2009
Follow-on offering$983K · 2009
Follow-on offering$1.5M · 2009
Follow-on offering$1.1M · 2009
Follow-on offering$205K · 2009
Follow-on offering$570K · 2009
Follow-on offering$675K · 2010
Follow-on offering$113K · 2011
Follow-on offering$157K · 2011
Follow-on offering$291K · 2011

Showing first 24 of 47 filings to keep the sequence readable.

Modeled valuation trajectory
$34.1M
Base estimate est.
$4.4M
Conservative case
$93.0M
Upside case
$18.2M
Modeled post-money

This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.

Pre-Seed · modeled $27.6M · 2009-09-142009Seed · modeled $55.0M · 2009-09-14Seed · modeled $76.2M · 2009-09-14Seed · modeled $72.2M · 2009-09-14Seed · modeled $62.5M · 2009-09-14Seed · modeled $57.3M · 2009-09-14Pre-Seed · modeled $28.9M · 2009-09-14Pre-Seed · modeled $18.5M · 2009-09-14Seed · modeled $72.2M · 2009-09-14Seed · modeled $75.8M · 2009-09-14Seed · modeled $68.7M · 2009-09-14Seed · modeled $65.8M · 2009-09-14Seed · modeled $61.7M · 2009-09-14Pre-Seed · modeled $33.4M · 2009-09-14Pre-Seed · modeled $54.3M · 2009-09-14Pre-Seed · modeled $54.3M · 2009-09-14Seed · modeled $64.7M · 2009-09-14Seed · modeled $48.2M · 2009-09-14Pre-Seed · modeled $11.3M · 2009-09-14Pre-Seed · modeled $31.4M · 2009-09-14Pre-Seed · modeled $37.3M · 2010-04-24Pre-Seed · modeled $6.2M · 2011-02-02Pre-Seed · modeled $8.6M · 2011-02-02Pre-Seed · modeled $16.0M · 2011-02-02Pre-Seed · modeled $6.2M · 2011-02-02Pre-Seed · modeled $14.2M · 2011-02-02Pre-Seed · modeled $7.9M · 2011-02-02Pre-Seed · modeled $6.8M · 2011-02-02Pre-Seed · modeled $5.5M · 2011-11-01Pre-Seed · modeled $15.3M · 2011-11-25Pre-Seed · modeled $33.1M · 2011-12-02Seed · modeled $45.5M · 2011-12-02Pre-Seed · modeled $38.6M · 2011-12-02Pre-Seed · modeled $42.8M · 2011-12-02Pre-Seed · modeled $18.3M · 2012-01-27Seed · modeled $17.6M · 2012-01-27Pre-Seed · modeled $18.3M · 2012-01-27Seed · modeled $13.3M · 2012-05-10Seed · modeled $6.2M · 2012-09-11Seed · modeled $14.4M · 2013-07-31Seed · modeled $5.9M · 2013-08-21Seed · modeled $16.7M · 2013-12-17Seed · modeled $11.1M · 2013-12-20Seed · modeled $4.4M · 2014-03-27Seed · modeled $55.5M · 2016-09-30Series A · modeled $180.8M · 2018-07-01Series A · modeled $34.1M · 2023-06-302023
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.0 yr
Elapsed time used
3.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$1.1M/yr
Capital velocity
16.8 yr
On record since
2009
First round
47
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$14.6M
Sector median$7.8M
Modeled value — vs sector median (estimate, all stages) 0.6× of median
This company$34.1M
Sector median$56.2M

Raised more than 88% of sector peers (real $). Modeled value above 79% of peers (estimate).

Full financing history

This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Initial offering$500K2009-09-14$2.8M$27.6M85%
Follow-on offering$1.2M2009-09-14$6.2M$55.0M85%
Follow-on offering$1.7M2009-09-14$8.6M$76.2M85%
Follow-on offering$1.6M2009-09-14$8.1M$72.2M85%
Follow-on offering$1.4M2009-09-14$7.0M$62.5M85%
Follow-on offering$1.3M2009-09-14$6.4M$57.3M85%
Follow-on offering$524K2009-09-14$2.9M$28.9M85%
Follow-on offering$335K2009-09-14$1.9M$18.5M85%
Follow-on offering$1.6M2009-09-14$8.1M$72.2M85%
Follow-on offering$1.7M2009-09-14$8.5M$75.8M85%
Follow-on offering$1.5M2009-09-14$7.7M$68.7M85%
Follow-on offering$1.5M2009-09-14$7.4M$65.8M85%
Follow-on offering$1.4M2009-09-14$6.9M$61.7M85%
Follow-on offering$606K2009-09-14$3.4M$33.4M85%
Follow-on offering$983K2009-09-14$5.5M$54.3M85%
Follow-on offering$983K2009-09-14$5.5M$54.3M85%
Follow-on offering$1.5M2009-09-14$7.3M$64.7M85%
Follow-on offering$1.1M2009-09-14$5.4M$48.2M85%
Follow-on offering$205K2009-09-14$1.1M$11.3M85%
Follow-on offering$570K2009-09-14$3.2M$31.4M85%
Follow-on offering$675K2010-04-24$3.8M$37.3M85%
Follow-on offering$113K2011-02-02$625K$6.2M85%
Follow-on offering$157K2011-02-02$869K$8.6M85%
Follow-on offering$291K2011-02-02$1.6M$16.0M85%
Follow-on offering$113K2011-02-02$625K$6.2M85%
Follow-on offering$257K2011-02-02$1.4M$14.2M85%
Follow-on offering$143K2011-02-02$792K$7.9M85%
Follow-on offering$123K2011-02-02$681K$6.8M85%
Follow-on offering$100K2011-11-01$556K$5.5M85%
Follow-on offering$278K2011-11-25$1.5M$15.3M85%
Follow-on offering$600K2011-12-02$3.3M$33.1M85%
Follow-on offering$1.0M2011-12-02$5.1M$45.5M85%
Follow-on offering$700K2011-12-02$3.9M$38.6M85%
Follow-on offering$775K2011-12-02$4.3M$42.8M85%
Follow-on offering$332K2012-01-27$1.8M$18.3M85%
Follow-on offering$396K2012-01-27$2.0M$17.6M85%
Follow-on offering$332K2012-01-27$1.8M$18.3M85%
Follow-on offering$300K2012-05-10$1.5M$13.3M85%
Follow-on offering$140K2012-09-11$700K$6.2M85%
Follow-on offering$325K2013-07-31$1.6M$14.4M85%
Follow-on offering$132K2013-08-21$660K$5.9M85%
Follow-on offering$375K2013-12-17$1.9M$16.7M85%
Follow-on offering$250K2013-12-20$1.3M$11.1M85%
Follow-on offering$100K2014-03-27$500K$4.4M85%
Follow-on offering$1.3M2016-09-30$6.3M$55.5M90%
Follow-on offering$5.0M2018-07-01$22.7M$180.8M90%
Follow-on offering$4.0M2023-06-30$18.2M$34.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Initial offering$500K2009-09-14
    • First recorded raise — entered as Initial offering.
    • 10 investors on this round.
  2. Follow-on offering$1.2M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× larger than the prior — scaling up.
    • 35 investors on this round.
  3. Follow-on offering$1.7M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 43 investors on this round.
  4. Follow-on offering$1.6M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 43 investors on this round.
  5. Follow-on offering$1.4M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 39 investors on this round.
  6. Follow-on offering$1.3M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 37 investors on this round.
  7. Follow-on offering$524K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  8. Follow-on offering$335K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  9. Follow-on offering$1.6M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.9× larger than the prior — scaling up.
    • 43 investors on this round.
  10. Follow-on offering$1.7M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 43 investors on this round.
  11. Follow-on offering$1.5M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 42 investors on this round.
  12. Follow-on offering$1.5M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 42 investors on this round.
  13. Follow-on offering$1.4M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 38 investors on this round.
  14. Follow-on offering$606K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 14 investors on this round.
  15. Follow-on offering$983K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× larger than the prior — scaling up.
    • 26 investors on this round.
  16. Follow-on offering$983K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 26 investors on this round.
  17. Follow-on offering$1.5M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 41 investors on this round.
  18. Follow-on offering$1.1M2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 31 investors on this round.
  19. Follow-on offering$205K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.3× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  20. Follow-on offering$570K2009-09-14
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.8× larger than the prior — scaling up.
    • 11 investors on this round.
  21. Follow-on offering$675K2010-04-24
    • Raised 7 mo later, in step with the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  22. Follow-on offering$113K2011-02-02
    • Raised 9 mo later, in step with the ~11 mo sector norm.
    • Round 6.0× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  23. Follow-on offering$157K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 7 investors on this round.
  24. Follow-on offering$291K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× larger than the prior — scaling up.
    • 7 investors on this round.
  25. Follow-on offering$113K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.6× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  26. Follow-on offering$257K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× larger than the prior — scaling up.
    • 7 investors on this round.
  27. Follow-on offering$143K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  28. Follow-on offering$123K2011-02-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 7 investors on this round.
  29. Follow-on offering$100K2011-11-01
    • Raised 9 mo later, in step with the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  30. Follow-on offering$278K2011-11-25
    • Came back fast: 1 mo vs the ~11 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
    • 1 investor on this round.
  31. Follow-on offering$600K2011-12-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× larger than the prior — scaling up.
    • 1 investor on this round.
  32. Follow-on offering$1.0M2011-12-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
    • 1 investor on this round.
  33. Follow-on offering$700K2011-12-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  34. Follow-on offering$775K2011-12-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  35. Follow-on offering$332K2012-01-27
    • Came back fast: 2 mo vs the ~11 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  36. Follow-on offering$396K2012-01-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  37. Follow-on offering$332K2012-01-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  38. Follow-on offering$300K2012-05-10
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  39. Follow-on offering$140K2012-09-11
    • Came back fast: 4 mo vs the ~11 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • Revenue band moved $0–$1M → No revenue.
    • 1 investor on this round.
  40. Follow-on offering$325K2013-07-31
    • Raised 11 mo later, in step with the ~11 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 5 investors on this round.
  41. Follow-on offering$132K2013-08-21
    • Came back fast: 1 mo vs the ~11 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  42. Follow-on offering$375K2013-12-17
    • Came back fast: 4 mo vs the ~11 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 1 investor on this round.
  43. Follow-on offering$250K2013-12-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  44. Follow-on offering$100K2014-03-27
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  45. Follow-on offering$1.3M2016-09-30
    • Raised again after 30 mo — slower than the ~11 mo sector norm.
    • Round 12.5× larger than the prior — scaling up.
    • 6 investors on this round.
  46. Follow-on offering$5.0M2018-07-01
    • Raised again after 21 mo — slower than the ~11 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
  47. Follow-on offering$4.0M2023-06-30
    • Raised again after 60 mo — slower than the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~4mo cadence
$4.0M
Modeled next size est.range $4.0M$6.4M
0.8×
Last step-up
$1.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John Gorman6 other2009-09
JOHN PAYNE6 other2013-07
BRIAN YOUNG2 other2012-09
John B. Payne2 other2023-06
Peter Vitulli2 other2009-09
Andrew A Dahl1 other2018-07
Andrew Dahl1 other2011-12
Howard Baer1 other2009-09
Keith R. Marchiando1 other2023-06
Nola E. Masterson1 other2023-06
Nola Masterson1 other2016-09
THOMAS COX1 other2013-07
Allison A. Cornell2023-06
CHRIS MAGGIORE2013-12
CHRISTOPHE MAGGIORE2016-09
Christopher D. Maggiore2023-06
Janet Crance2009-09
John Crissman2009-09
Philip Marshall Rice II2018-07
PHILIP RICE2012-09
PHILIP RICE II2016-09
Phillip Rice2011-11
ROBERT RONDEAU2016-09
Steven Warner2009-09
Registry & provenance

Zivo Bioscience, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1101026
SEC CIK
2023
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Northsight Capital, Inc.Business ServicesSeries A$8.8M$4.7Mnetwork2 shared operators · same stage
Epsilon3, Inc.BiotechSeries A$15.0M$217.3Msame sector · same stage
Tamarind Bio, Inc.BiotechSeries A$13.6M$47.6Msame sector · same stage
Mindstate Design Labs, Inc.BiotechSeries A$12.7M$56.2Msame sector · same stage
CHD Bioscience, Inc.BiotechSeries A$18.7M$3.3Msame sector · same stage
Montlake Bioscience Inc.BiotechSeries A$11.3M$410.3Msame sector · same stage
LOCAL CorpOther TechnologySeries A$13.8M$126.7Mnetwork1 shared operator · same stage
Kaneh Bosm Biotechnology Inc.BiotechSeries A$10.9M$90.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
AgNovos Bioscience, Inc.BiotechSeries B$119.9M83%
Ambra Bioscience LLCBiotechSeed$46.6M81%
INVO Bioscience, Inc.BiotechSeed$29.2M81%
Imago BioSciences, Inc.Biotech / PharmaSeries C$2.7B81%
Zorion Medical, Inc.HealthtechSeed$22.1M80%
Kanvas Biosciences, Inc.Biotech / PharmaSeries A$23.7M80%
Vigilant Biosciences, Inc.Biotech / PharmaSeries B$16.5M80%
Escalante Bioscience, Inc.BiotechSeries A$38.1M80%
Frequently asked
How much funding has Zivo Bioscience, Inc. raised?
Zivo Bioscience, Inc. has raised approximately $14.6M in disclosed capital across 16 recorded financing rounds, aggregated from public filings.
What is Zivo Bioscience, Inc.'s estimated valuation?
Provath's modeled valuation for Zivo Bioscience, Inc. is approximately $34.1M (modeled range $4.4M–$93.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Zivo Bioscience, Inc. at?
Zivo Bioscience, Inc. shows a recurring offering pattern rather than a clean VC stage progression. Its most recent recorded round closed around Fri Jun 30.
What does Zivo Bioscience, Inc. do and where is it based?
Zivo Bioscience, Inc. operates in the Biotech sector, based in Bloomfield Hills.
Explore related

See where Zivo Bioscience, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Zivo Bioscience, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.